Back to Browse Journals » Vascular Health and Risk Management » Volume 3 » Issue 6

A review of thiazolidinediones and metformin in the treatment of type 2 diabetes with focus on cardiovascular complications

Authors Behzad Molavi, Negah Rassouli, Suveer Bagwe, Neda Rasouli

Published 15 January 2008 Volume 2007:3(6) Pages 967—973

Behzad Molavi1, Negah Rassouli2, Suveer Bagwe1, Neda Rasouli2

Central Arkansas Veterans Healthcare System and University of Arkansas for Medical sciences, 1Division of cardiology and 2Division of Endocrinology, College of Medicine, Little Rock, Arkansas, USA

Abstract: The rising incidence of obesity and insulin resistance to epidemic proportions has closely paralleled the surge in the prevalence of diabetes and outpaced therapeutic advances in diabetes prevention and treatment. Current evidence points to obesity induced oxidative stress and chronic inflammation as the common denominators in the evolution of insulin resistance and diabetes. Of all the hypoglycemic agents in the pharmacological arsenal against diabetes, thiazolidinediones, in particular pioglitazone, as well as metformin appear to have additional effects in ameliorating oxidative stress and inflammation; rendering them attractive tools for prevention of insulin resistance and diabetes. In addition to their hypoglycemic and lipid modifying properties, pioglitazone and metformin have been shown to exert anti-oxidative and anti-inflammatory effects in vascular beds, potentially slowing the accelerated atherosclerosis in diabetes, which is the major cause of morbidity and mortality in the affected population. The combination of pioglitazone and metformin would thus appear to be an effective pharmacological intervention in prevention and treatment of diabetes. Finally, this review will address the currently available evidence on diabetic cardiomyopathy and the potential role of combination therapy with pioglitazone and metformin.

Keywords: insulin resistance, oxidative stress, inflammation, pioglitazone, metformin, atherosclerosis, diabetic cardiomyopathy

Download Article [PDF] 

Readers of this article also read:

PLGA nanofiber membranes loaded with epigallocatechin-3-O-gallate are beneficial to prevention of postsurgical adhesions

Shin YC, Yang WJ, Lee JH, Oh JW, Kim TW, Park JC, Hyon SH, Han DW

International Journal of Nanomedicine 2014, 9:4067-4078

Published Date: 22 August 2014

How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study

Penfornis A, Blicklé JF, Fiquet B, Quéré S, Dejager S

Vascular Health and Risk Management 2014, 10:341-352

Published Date: 13 June 2014

Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes

Floris Alexander van de Laar

Vascular Health and Risk Management 2008, 4:1189-1195

Published Date: 5 December 2008

Successful resection of the recurrence of a cavernous malformation of the optic chiasm

Martin Scholz, Albrecht Harders, Sebastian Lücke, Ioannis Pechlivanis, Martin Engelhardt, Kirsten Schmieder

Clinical Ophthalmology 2008, 2:945-949

Published Date: 5 December 2008

Treatment of allergic conjunctivitis with olopatadine hydrochloride eye drops

Eiichi Uchio

Clinical Ophthalmology 2008, 2:525-531

Published Date: 12 September 2008

Diagnosis with ECG-gated MDCT of floating thrombus in aortic arch in a patient with type-A dissection

Domenico Lumia, Gianpaolo Carrafiello, Domenico Laganà, Andrea Musazzi, Andrea Giorgianni, et al

Vascular Health and Risk Management 2008, 4:735-739

Published Date: 6 June 2008

Differential diagnoses and management strategies in patients with schizophrenia and bipolar disorder

A Carlo Altamura, Jose M Goikolea

Neuropsychiatric Disease and Treatment 2008, 4:311-317

Published Date: 8 February 2008

Bisoprolol in the treatment of chronic heart failure

Pascal de Groote, Pierre-Vladimir Ennezat, Fréderic Mouquet

Vascular Health and Risk Management 2007, 3:431-439

Published Date: 15 September 2007

Treatment update: thiazolidinediones in combination with metformin for the treatment of type 2 diabetes

John M Stafford, Tom Elasy

Vascular Health and Risk Management 2007, 3:503-510

Published Date: 15 September 2007

Rimonabant for treating tobacco dependence

Michael B Steinberg, Jonathan Foulds

Vascular Health and Risk Management 2007, 3:307-311

Published Date: 15 July 2007